Quantitative Investment Management LLC Purchases New Shares in Stryker Corporation $SYK

Quantitative Investment Management LLC purchased a new position in shares of Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,942 shares of the medical technology company’s stock, valued at approximately $1,870,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sankala Group LLC purchased a new stake in shares of Stryker during the fourth quarter valued at approximately $26,000. Godfrey Financial Associates Inc. purchased a new position in Stryker in the fourth quarter worth $26,000. United Financial Planning Group LLC purchased a new position in Stryker in the third quarter worth $27,000. Atlas Capital Advisors Inc. bought a new position in Stryker in the 4th quarter valued at $27,000. Finally, Gables Capital Management Inc. purchased a new stake in shares of Stryker during the 2nd quarter valued at $25,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 300,000 shares of Stryker stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the transaction, the director owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. The trade was a 11.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Dylan Bram Crotty sold 441 shares of the company’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 351,267 shares of company stock worth $118,197,701 in the last quarter. 4.60% of the stock is owned by company insiders.

Stryker Stock Performance

NYSE SYK opened at $324.32 on Tuesday. The firm has a market cap of $124.40 billion, a P/E ratio of 33.61, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The company’s 50 day moving average is $329.49 and its 200-day moving average is $331.03. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker’s revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the business earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts predict that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is 36.48%.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on SYK shares. Citizens Jmp cut their price target on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a report on Monday, August 3rd. Truist Financial raised their price objective on shares of Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a report on Friday, July 31st. Evercore set a $350.00 target price on shares of Stryker in a research note on Monday, July 6th. JPMorgan Chase & Co. decreased their price target on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Finally, Barclays reduced their price objective on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a report on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.